Zydelig

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, B-Cell Lymphomas
Treatment
5 FDA approvals
3 Active Studies for Zydelig

What is Zydelig

IdelalisibThe Generic name of this drug
Treatment SummaryIdelalisib is a medication used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). It works by targeting an enzyme called phosphatidylinositol-4,5-bisphosphate 3-kinase (PI-3K) that is involved in cell growth, proliferation, and survival. By inhibiting this enzyme, idelalisib can induce the death of cancer cells and block certain cell signaling pathways that are involved in the movement of B-cells
Zydeligis the brand name
image of different drug pills on a surface
Zydelig Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zydelig
Idelalisib
2014
2

Approved as Treatment by the FDA

Idelalisib, also known as Zydelig, is approved by the FDA for 5 uses which include Leukemia, Lymphocytic, Chronic, B-Cell and relapsed follicular B-cell non-Hodgkin's lymphoma .
Leukemia, Lymphocytic, Chronic, B-Cell
Used to treat Relapsed Chronic Lymphocytic Leukemia in combination with Rituximab
relapsed follicular B-cell non-Hodgkin's lymphoma
relapsed Small Lymphocytic Lymphoma
B-Cell Lymphomas
Chronic Lymphocytic Leukemia

Effectiveness

How Zydelig works in the bodyIdelalisib works by blocking a certain enzyme, P110δ. This enzyme is found in white blood cells and helps them to grow, move, and survive. By blocking P110δ, idelalisib causes cancer cells to die and stops certain cell signals that help the movement and settling of B-cells in the lymph nodes and bone marrow. This medication has also been shown to stop the movement and sticking of cancer cells, reducing their ability to survive.

When to interrupt dosage

The proposed amount of Zydelig is contingent upon the specified condition, such as B-Cell Lymphomas, Chronic Lymphocytic Leukemia and Relapsed Chronic Lymphocytic Leukemia. The dosage is dependent on the administration technique featured in the table below.
Condition
Dosage
Administration
Chronic Lymphocytic Leukemia
100.0 mg, 150.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Leukemia, Lymphocytic, Chronic, B-Cell
100.0 mg, 150.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
B-Cell Lymphomas
100.0 mg, 150.0 mg,
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Zydelig Contraindications
Condition
Risk Level
Notes
Toxic Epidermal Necrolysis
Do Not Combine
anaphylaxis
Do Not Combine
There are 20 known major drug interactions with Zydelig.
Common Zydelig Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Idelalisib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Idelalisib is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Idelalisib is combined with Antilymphocyte immunoglobulin (horse).
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Idelalisib.
Baricitinib
Major
The risk or severity of adverse effects can be increased when Idelalisib is combined with Baricitinib.
image of a doctor in a lab doing drug, clinical research

Zydelig Novel Uses: Which Conditions Have a Clinical Trial Featuring Zydelig?

At present, 7 clinical trials are underway to determine the potential of Zydelig in treating B-Cell Lymphomas, Chronic Lymphocytic Leukemia and Relapsed Chronic Lymphocytic Leukemia.
Condition
Clinical Trials
Trial Phases
B-Cell Lymphomas
0 Actively Recruiting
Chronic Lymphocytic Leukemia
0 Actively Recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
3 Actively Recruiting
Phase 1

Zydelig Reviews: What are patients saying about Zydelig?

5Patient Review
8/2/2016
Zydelig for Relapsed Follicular B-Cell Non-Hodgkin Lymphoma
Zydelig has given me 13 months of remission after years of grueling chemotherapy and a stem cell transplant relapse. I've had no side effects and am finally enjoying a good quality of life!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zydelig

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you take Zydelig?

"The rituximab treatment cycle lasts for 28 days (4 weeks) and you usually have a total of 8 doses. The idelalisib tablets are taken twice a day and the treatment can last for up to 6 cycles. You continue idelalisib for as long as it is working and the side effects aren't bad."

Answered by AI

How is Zydelig administered?

"The recommended dosage of Zydelig is 150 mg twice daily, oral, with or without food, until disease progression or toxicity becomes unacceptable."

Answered by AI

What kind of drug is idelalisib?

"Idelalisib is a cancer medication that works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells."

Answered by AI

Who makes Zydelig?

"The U.S. Food and Drug Administration (FDA) today approved Zydelig® (idemalisib), a kinase inhibitor, for two indications: in combination with rituximab for the treatment of patients with relapsed/refractory follicular lymphoma who have received at least two prior therapies, and as a single-agent therapy for the treatment of patients with relapsed/refractory small lymphocytic lymphoma (SLL).

The FDA has approved Gilead Sciences' Zydelig for the treatment of two types of blood cancer - follicular lymphoma and small lymphocytic lymphoma. The drug is approved for use in combination with rituximab for the treatment of patients with relapsed/refractory follicular lymphoma who have received at least two prior therapies. It is also approved as a single-agent therapy for the treatment of patients with relapsed/refractory small lymphocytic lymphoma."

Answered by AI

Is Zydelig a chemotherapy?

"Targeted therapies are a type of cancer treatment that uses drugs or other substances to more precisely identify and attack cancer cells while doing little damage to normal cells.

The drug Zydelig®, also known by its generic name idelalisib, is a type of targeted cancer therapy. This means that it is designed to specifically target cancer cells while doing little damage to normal, healthy cells."

Answered by AI

What is Zydelig used for?

"This drug is used to treat certain types of cancer, such as chronic lymphocytic leukemia-CLL, follicular B-cell non-Hodgkin's lymphoma, and small lymphocytic lymphoma-SLL. Idelalisib is a type of drug called a kinase inhibitor, which works by slowing or stopping the growth of cancer cells."

Answered by AI

Clinical Trials for Zydelig

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top